Abstract
This study describes the development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for determination of cediranib in human plasma. The method was sensitive, selective and rapid for the analysis of cediranib. A liquid-liquid extraction method was used and chromatographic separation was performed on a C-18,UPLC, BEHTM column (50 x 2.1 mm, i d 1 7 mu m, Waters, USA) with a run time of 2.6 minutes. Crizotinib was used as internal standard. Multiple reaction monitoring ion transitions used for detection were m/z 451.43 -> 112.02 and m/z 450.0 -> 260.0 for cediranib and internal standard, respectively. The linearity of the assay was found to be between 1-300 ng/mL for cediranib in human plasma. The intra- and inter-assay precision relative standard deviations did not exceed 11.52 and mean extraction recovery was found to be 74.74 +/- 2.29.